- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor CB‑839
- Arginase Inhibitor INCB001158
- Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
Science
Publications and Presentations
Check out our publications and poster presentations.
March 2016
Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid CellsKeystone Symposia on Cancer Immunotherapy
December 2015
Metabolomic, Proteomic and Genomic Profiling Identifies Biomarkers of Sensitivity to Glutaminase Phase I Study of CB-839, a First-in-class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients With Relapsed/ Refractory Leukemia Phase I Study of CB-839, a First-in-class, Glutaminase Inhibitor in Patients With Multiple Myeloma and LymphomaAmerican Society of Hematology
November 2015
November 2015
November 2015
Our Pipeline
We are focused on solid tumors for
which new treatments are urgently needed.